✦ LIBER ✦

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

✍ Scribed by Kelly L. Sullivan; Joseph F. Staffetti; Robert A. Hauser; Peter B. Dunne; Theresa A. Zesiewicz

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 45 KB
Volume: 21
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20666

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society

📜 SIMILAR VOLUMES

Macrogol for the treatment of constipati

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study

✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

Sertraline for the treatment of depressi

Sertraline for the treatment of depression in parkinson's disease

✍ Dr. Robert A. Hauser; Theresa A. Zesiewicz 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 2 views

## Abstract Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inh

Excess burden of constipation in Parkins

Excess burden of constipation in Parkinson's disease: A pilot study

✍ Julie Kaye; Heather Gage; Alan Kimber; Lesley Storey; Patrick Trend 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

An analysis was undertaken of clinic-based questionnaires that asked people with Parkinson's disease and a control group of older people without a known neurological condition about their experiences of constipation. People with Parkinson's disease report higher constipation on a validated objective

Treatment of Parkinson's disease in Spai

Treatment of Parkinson's disease in Spain

✍ Francisco Grandas; Jaime Kulisevsky 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

## Abstract To assess the patterns of drug use in Parkinson's disease in Spain, information about the clinical characteristics and current treatment of 1,803 parkinsonian patients was obtained from a nationwide survey, involving 241 physicians with practice based on the different assistance levels

The initial treatment of Parkinson's dis

The initial treatment of Parkinson's disease

✍ Stewart A. Factor 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB 👁 3 views

Viral vectors in the treatment of Parkin

Viral vectors in the treatment of Parkinson's disease

✍ David S. Latchman; Robert S. Coffin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

s disease is an obvious target for the development of gene therapy procedures which could involve both the delivery of the gene encoding tyrosine hydroxylase to boost dopamine production or the delivery of genes encoding neurotrophic factors such as GDNF to promote the survival of dopaminergic neuro